During the last session, Tango Therapeutics Inc (NASDAQ:TNGX)’s traded shares were 0.49 million, with the beta value of the company hitting 0.81. At the end of the trading day, the stock’s price was $3.15, reflecting an intraday gain of 0.64% or $0.02. The 52-week high for the TNGX share is $13.01, that puts it down -313.02 from that peak though still a striking 14.29% gain since the share price plummeted to a 52-week low of $2.70. The company’s market capitalization is $338.37M, and the average intraday trading volume over the past 10 days was 1.44 million shares, and the average trade volume was 1.92 million shares over the past three months.
Tango Therapeutics Inc (TNGX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.11. TNGX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Tango Therapeutics Inc (NASDAQ:TNGX) trade information
Tango Therapeutics Inc (TNGX) registered a 0.64% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.64% in intraday trading to $3.15, hitting a weekly high. The stock’s 5-day price performance is 0.96%, and it has moved by -14.63% in 30 days. Based on these gigs, the overall price performance for the year is -67.32%. The short interest in Tango Therapeutics Inc (NASDAQ:TNGX) is 8.06 million shares and it means that shorts have 4.51 day(s) to cover.
The consensus price target of analysts on Wall Street is $15.5, which implies an increase of 79.68% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $13 and $18 respectively. As a result, TNGX is trading at a discount of -471.43% off the target high and -312.7% off the low.
Tango Therapeutics Inc (TNGX) estimates and forecasts
Statistics show that Tango Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Tango Therapeutics Inc (TNGX) shares have gone down -63.20% during the last six months, with a year-to-date growth rate less than the industry average at -10.19% against 16.80.
While earnings are projected to return -11.20% in 2025.
TNGX Dividends
Tango Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Tango Therapeutics Inc (NASDAQ:TNGX)’s Major holders
Tango Therapeutics Inc insiders own 12.84% of total outstanding shares while institutional holders control 100.71%, with the float percentage being 115.55%. TRV GP IV, LLC is the largest shareholder of the company, while 189.0 institutions own stock in it. As of 2024-06-30, the company held over 19.2 million shares (or 17.751% of all shares), a total value of $164.75 million in shares.
The next largest institutional holding, with 13.33 million shares, is of ECOR1 CAPITAL, LLC’s that is approximately 12.3237% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $114.38 million.
